"33% Higher Risk" Popular Blood Pressure Drug Linked to Faster Kidney Decline in Adults With Type 2 Diabetes

A blood pressure medication prescribed to millions of adults is drawing fresh attention after researchers linked it to a higher risk of serious kidney complications in people living with type 2 diabetes.

Health records from 31,031 adults treated between 2016 and 2021 were reviewed. Every participant was already taking renin-angiotensin system inhibitors and SGLT2 inhibitors, two therapies commonly used to help protect kidney function.

Adults who also received dihydropyridine calcium channel blockers, known as DCCBs, faced a 33% higher risk of major adverse kidney events than those using alternative blood pressure medications, according to research presented at the 63rd European Renal Association Congress. Those events included a decline of at least 40% in kidney filtration function or progression to kidney failure requiring dialysis or transplantation.

Dialysis centers and transplant waiting lists represent the outcomes physicians work to avoid. Because DCCBs are frequently prescribed when additional blood pressure control is needed, the findings could carry significance for large numbers of diabetes patients.

"Our findings raise important questions about whether these medications are always the best option for patients already receiving modern kidney-protective therapies," lead author Dr. Timna Agur said when discussing the analysis. That concern stems from the possibility that some treatment combinations may place extra strain on kidneys already vulnerable to damage.

Researchers believe the explanation may involve pressure changes inside the kidney's microscopic filtering units. The medication relaxes blood vessels entering those filters, a process that could expose delicate tissue to greater stress over time.

The analysis does not establish direct cause and effect. Investigators described the work as observational and said additional clinical testing will be needed before prescribing recommendations change.

People taking blood pressure medication should not stop treatment without medical guidance. Heart protection, stroke prevention and kidney preservation remain critical priorities for adults living with diabetes.

For families confronting the possibility of dialysis or transplant surgery, medication choice can carry long-term consequences. The Glasgow research adds another factor for physicians and patients to weigh when deciding how best to control blood pressure while protecting kidney health.